ARPharM

Video Clips



Code for Disclosure of Transfers of Value by Pharmaceutical Companies to Healthcare Professionals and Health Organizations

E-mail Print PDF

Healthcare professionals and healthcare organisations with whom they work provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. This expertise makes an important contribution to the industry’s efforts to improve the quality of patient care, with benefits for individuals and society at large. Healthcare professionals and healthcare organisations should be fairly compensated for the legitimate expertise and services they provide to the industry.

Healthcare professionals and healthcare organisations with whom they work provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. This expertise makes an important contribution to the industry’s efforts to improve the quality of patient care, with benefits for individuals and society at large. Healthcare professionals and healthcare organisations should be fairly compensated for the legitimate expertise and services they provide to the industry.

The Association of Research-based Pharmaceutical Manufacturers in Bulgaria believes that interactions between the pharmaceutical industry and healthcare professionals have a profound and positive influence on the quality of patient treatment and the value of future research. At the same time, the integrity of the decision of a healthcare professional to prescribe a medicine is one of the pillars of the healthcare system. The Association recognises that interactions between the industry and healthcare professionals can create the potential for conflicts of interest. Consequently, the Association has adopted codes and principles to ensure that these interactions meet the high standards of integrity that patients, governments and other stakeholders expect.

To continue to be successful, self-regulation should meet the changing needs of society and in particular, the growing expectation that the interaction between corporations and society are conducted not only with integrity, but also with transparency.

In accordance with these guidelines, the Association believes that it is crucial for the future success of the pharmaceutical industry to respond to the heightened expectations of the general public. Therefore, the Association decided that the current Code of Ethics of Research-based Pharmaceutical Industry in Bulgaria ("Code of Ethics") and the Code of the Interaction of the pharmaceutical industry and patient organizations in Bulgaria ("Code for PO”) should be supplemented by requirements for detailed disclosure regarding the nature and scale of the interactions between the industry and healthcare professionals and organisations. The Association hopes that by taking this step, it will enable public scrutiny and understanding of these relationships, and thus contribute to the trust of stakeholders in the pharmaceutical industry

The Association believes that the demand of patients and other stakeholders for transparency of these interactions is significant. The Association recognizes that such disclosure may raise issues related to the disclosure of private data, but believes that transparency can be achieved without sacrificing the legitimate privacy interests of healthcare professionals.

Attached files:

pdfCode for Disclosure of Transfers of Value by Pharmaceutical Companies to Healthcare Professionals and Health Organizations